D Orazio & Associates Inc. Takes $218,000 Position in Cencora, Inc. $COR

D Orazio & Associates Inc. acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 728 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Cencora by 8.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after acquiring an additional 787,858 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Cencora by 7.2% during the 1st quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock valued at $1,507,599,000 after purchasing an additional 363,402 shares during the last quarter. Boston Partners raised its position in Cencora by 8.1% in the 1st quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after purchasing an additional 404,093 shares during the period. Geode Capital Management LLC raised its position in Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after purchasing an additional 284,229 shares during the period. Finally, Invesco Ltd. lifted its stake in Cencora by 42.1% in the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.5%

COR opened at $365.06 on Friday. Cencora, Inc. has a one year low of $223.92 and a one year high of $366.17. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The business has a 50 day simple moving average of $319.97 and a two-hundred day simple moving average of $301.57. The firm has a market capitalization of $70.78 billion, a price-to-earnings ratio of 37.56, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is 30.19%.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 41,544 shares of company stock worth $12,230,941 in the last ninety days. Insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on COR. JPMorgan Chase & Co. raised their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Mizuho boosted their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.